Amgen settles patent lawsuit over biosimilar of J&J’s big-selling Stelara
By Blake Brittain (Reuters) -Johnson & Johnson has settled its lawsuit over Amgen Inc’s proposed biosimilar version of J&J’s top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court. Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company…
